Last reviewed · How we verify
VABYSMO (FARICIMAB-SVOA)
VABYSMO (generic name: FARICIMAB-SVOA) is a drug developed by GENENTECH INC. It is currently FDA-approved for Exudative age-related macular degeneration, Macular edema due to diabetes mellitus.
Faricimab is an antibody that inhibits Angiopoietin-2, a protein involved in angiogenesis. It is being studied as a treatment for various eye conditions, including macular edema, central retinal vein occlusion, hemiretinal vein occlusion, neovascular age-related macular degeneration, and polypoidal choroidal vasculopathy.
At a glance
| Generic name | FARICIMAB-SVOA |
|---|---|
| Sponsor | GENENTECH INC |
| Target | Angiopoietin-2, Vascular endothelial growth factor A |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
Common side effects
- Cataract
- Conjunctival hemorrhage
- Vitreous detachment
- Vitreous floaters
- Intraocular pressure increased
- Eye pain
- Intraocular inflammation
- Eye irritation
- Lacrimation increased
- Ocular discomfort
Serious adverse events
- Endophthalmitis
- Retinal detachment
- Rhegmatogenous retinal detachment
- Retinal tear
- Retinal vasculitis with or without retinal vascular occlusion
- Thromboembolic events
- Corneal abrasion
- Vitreous hemorrhage
- Hypersensitivity
Key clinical trials
- A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE) (Phase 3)
- A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration ( (Phase 3)
- Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients (Phase 2)
- Real-World, Long-Term Data Collection to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER STUDY) (N/A)
- A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (YOSEMITE) (Phase 3)
- An Exploratory, Prospective, Multi-Center, Open-Label, Single-Arm, Interventional, Phase IIB Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Patients With Diabe (Phase 2)
- A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or (Phase 3)
- Efficacy of Faricimab in Patients With Subretinal Hyperreflective Material Associated With Type 2 or Mixed Neovascular Membranes Assessed by Multimodal Imaging (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VABYSMO CI brief — competitive landscape report
- VABYSMO updates RSS · CI watch RSS
- GENENTECH INC portfolio CI
Frequently asked questions about VABYSMO
What is VABYSMO?
What is VABYSMO used for?
Who makes VABYSMO?
What is the generic name of VABYSMO?
What development phase is VABYSMO in?
What are the side effects of VABYSMO?
What does VABYSMO target?
Related
- Target: All drugs targeting Angiopoietin-2, Vascular endothelial growth factor A
- Manufacturer: GENENTECH INC — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Exudative age-related macular degeneration
- Indication: Drugs for Macular edema due to diabetes mellitus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing